• Wolf Lehmann, CFO, and Achim Schalk, member of the Management Board, will assume his duties until further notice

Uwe Röhrhoff has stepped down from his role as interim CEO of Gerresheimer AG at his own request. He had assumed the position at the request of the Supervisory Board in November 2025, during a challenging period for the company. He had been appointed interim CEO of the company effective November 1, 2025, for a term ending no later than October 2026.

During his tenure, together with his fellow Management Board members Wolf Lehmann and Achim Schalk—who were also newly appointed in 2025—he succeeded in stabilising the company and comprehensively addressing key issues.

This includes the fact that, through the agreement signed at the end of July 2026 to sell the US subsidiary Centor and the global Primary Packaging Plastics business, Gerresheimer will be able to significantly optimise its capital and financing structure and substantially reduce its leverage. Wolf Lehmann and Achim Schalk will assume his duties until further notice.

“After successfully navigating the complex challenges of the past few months together with his colleagues on the Management Board, Mr Röhrhoff has decided to step down from his role as interim CEO a few weeks before the end of his term,” said Dr Axel Herberg, chairman of the Supervisory Board of Gerresheimer AG.

“We respect his decision and would like to express our sincere gratitude for his tremendous dedication over the past few months, which reflects his commitment to Gerresheimer. Over the past few months, he has played a key role in bringing Gerresheimer back on a sustainable path for the future.”

About Gerresheimer

Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of primary packaging solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry.

The product range includes infusion, dropper and syrup bottles, tablet containers, vials, syringes, pens, auto-injectors, inhalers, ampoules, cartridges, on-body devices as well as digital solutions for therapy support. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient.

Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With 39 production sites in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma, the Group generated revenues of around EUR 2.3bn in 2025 and employs over 13,000 people. Gerresheimer AG is listed on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).

www.gerresheimer.com